Myotonic dystrophy type 1 (DM1), a dominant hereditary muscular dystrophy, is caused by an abnormal expansion of a (CTG) n trinucleotide repeat in the 3 0 UTR of the human dystrophia myotonica protein kinase (DMPK) gene. As a consequence, mutant transcripts containing expanded CUG repeats are retained in nuclear foci and alter the function of splicing regulatory factors members of the MBNL and CELF families, resulting in alternative splicing misregulation of specific transcripts in affected DM1 tissues. In the present study, we treated DMSXL mice systemically with a 2 0 -4 0 -constrained, ethyl-modified (ISIS 486178) antisense oligonucleotide (ASO) targeted to the 3 0 UTR of the DMPK gene, which led to a 70% reduction in CUG exp RNA abundance and foci in different skeletal muscles and a 30% reduction in the heart. Furthermore, treatment with ISIS 486178 ASO improved body weight, muscle strength, and muscle histology, whereas no overt toxicity was detected. This is evidence that the reduction of CUG exp RNA improves muscle strength in DM1, suggesting that muscle weakness in DM1 patients may be improved following elimination of toxic RNAs.
INTRODUCTION
Myotonic dystrophy type 1 (DM1), the most common form of muscular dystrophy in adults, with an incidence of 1:15,000, is a multisystemic disorder characterized by myotonia, progressive muscle wasting, cardiac conduction defects, as well as endocrine deficiencies and cognitive impairments. 1 A severe congenital form (CDM1) of this disease is characterized by neonatal hypotonia, facial weakness, respiratory and feeding difficulties, and high neonatal mortality (16% versus 19:1,000 in the population). Available data suggest that CDM1 seems to be caused by delayed skeletal muscle and brain maturation, [1] [2] [3] [4] whereas the adult form of DM1 appears to result from a degenerative process. DM1 is caused by an expanded (CTG) n repeat, where n varies from 50 to several thousand, in the 3 0 UTR of the dystrophia myotonica protein kinase (DMPK) gene. 5 The most commonly accepted mecha-nistic explanation is that the nuclear accumulation of transcripts containing CUG expansions sequesters the RNA-binding protein MBNL1 and stabilizes CELF1 via hyperphosphorylation. [6] [7] [8] [9] [10] [11] The deregulated expression and activity of these RNA-binding proteins in individuals affected by DM1 leads to perturbations in the alternative splicing of key genes. 7, 12 The extent of the contribution of spliceopathy to CDM1 pathogenesis, however, remains unclear.
Transgenic mouse models have been developed to investigate DM1 etiology. [13] [14] [15] Among these models, the HSA LR mouse expressing 250 CTG repeats under the human skeletal actin promoter 13 and the DMSXL mouse, which harbors a mutant form of the human DMPK gene that carries >1,000 CTG repeats and is under the regulation of its own promoter. Homozygous DMSXL mice display several phenotypical manifestations of the disease and provide the only available DM1 model for screening of ASOs targeting DMPK regions outside the repeats. 15, 16 It was previously shown that a steric blocking ASO targeting the CUG exp repeats in HSA LR mice could reverse a subset of mis-spliced RNAs. 17 Using the ASO-induced RNA cleavage strategy, the same group showed that targeting the chimeric actin gene in HSA LR mice could correct myotonia and also that targeting the DMPK gene was possible following systemic injections in asymptomatic DM1 mice. 18 We hypothesized the reduction in the level of mutant transcripts by targeting the DMPK transcript with an ASO-inducing RNA cleavage would alleviate pathological phenotypic traits in a mouse model of DM1, such as the loss of strength. We recently identified two ASOs, a 2 0 -4 0 -constrained ethyl (cEt) and a 2 0 -O-methoxyethyl (MOE) gapmers, which were able to achieve strong knockdown of DMPK mutant transcripts in DM1 cells and in a mouse model of DM1. 18, 19 RESULTS ISIS 445569 and ISIS 486178 Reduce DMPK mRNA Levels in Human DM1 Muscle Satellite Cells Over 3,000 ASOs containing either MOE, cEt, or a combination of both chemistries were previously screened for inhibition of human DMPK expression. 19 We identified two ASOs, the first bearing MOE modifications complementary to a region in exon 15 upstream to the (CUG) n repeats within the 3 0 UTR of DMPK, and the second bearing cEt modifications complementary to a region in exon 15 downstream to the aforementioned (CUG) n repeat, which exhibited particularly high potency ( Figure 1A) . ISIS 445569 and ISIS 486178 are 100% complementary to human DMPK gene; however, ISIS 486178 is also 100% complementary to the monkey and mouse Dmpk gene. Human DM1 muscle satellite cells were transfected with different concentrations (1, 5, 10, 20, 50, 125, 250 , 500, and 1,000 nM) of each oligonucleotide in the presence of Lipofectamine 2000 transfection reagent (Invitrogen). Blind analysis for RNA foci was performed after 2 days of differentiation. Quantification of nuclear foci, as identified by fluorescence in situ hybridization (FISH), revealed a dose-dependent disappearance of nuclear foci ( Figure 1B ) in human DM1 myotubes, with a maximum effect (>90% of foci disappearance; Figure 1C ) occurring at 20 nM for both ASOs ( Figure S1 ). Northern blot analysis confirmed that both ASOs induced a 90% reduction of the mutant transcripts (Figures 1D and 1E). As expected, because both ASOs were not specific for the mutant transcripts, a 70% reduction of the wild-type DMPK transcripts was also observed. Nuclear redistribution of MBNL1 also occurred after treatment with both ASOs ( Figure S2 ), indicating that CUG exp repeats are effectively degraded after cleavage events at either the 5 0 or 3 0 side of the repeat tract at the site targeted by the respective ASOs.
In a previous study, we identified a set of mis-spliced RNAs present in human DM1 muscle satellite cell cultures 20 that can be used to monitor alternative splicing corrections 48 hr after transfection. Treatment of DM1 cells with both ASOs consistently corrected the mis-splicing of SORBS1, CAMK2G, DMD, PDLIM3, and TTN transcripts ( Figure 1F ).
ISIS 445569 and ISIS 486178 Are Well Tolerated in Normal Myotubes
In order to assess the potential cellular toxicity of the two ASOs under study, a microarray was performed in normal myotubes treated with these ASOs at ten times their optimal concentration. Using gene ontology (GO) assignments to categorize genes for their involvement in apoptosis, cytotoxicity, and inflammation processes, no genes assigned to these GO categories were significantly affected (i.e., by a change R2-fold). Other genes affected by ISIS 486178 are listed in Table S1 . Moreover, we performed a cell apoptosis and necrosis assay ( Figure S3 ) and were unable to detect any significant cell-death-associated event. Therefore, ISIS 445569 and ISIS 486178 appeared to display efficacy and tolerability in cell culture, supporting advancing into in vivo studies.
Systemic Administration of ISIS 445569 and ISIS 486178 Reduce DMPK mRNA Levels in DMSXL Mice
On the basis of previous data, experimental procedures were done in homozygous female mice rather than in males because muscle function analysis was more consistent. 15 We evaluated these two ASOs in homozygous DMSXL mice by subcutaneous (s.c.) injection of 25 mg/kg (ISIS 486178) and 50 mg/kg (ISIS 445569) of ASO biweekly for the first 4 weeks, and then once a week for the following 5 weeks. Dosage was chosen based on dose-response experiments previously performed in heterozygous DMSXL mice. 19 After 9 weeks of administration (13 injections), ASOs reduced the number of nuclear foci by 70% and 40% in the quadriceps (Figures 2A and S4 ) for ISIS 486178 and ISIS 445569, respectively. Furthermore, RT-qPCR confirmed these numbers, with an average of 66% (ISIS 486178) and 41% (ISIS 445569) reduction in human mutant DM1 transcripts in six skeletal muscles (tibialis anterior, soleus, quadriceps, latissimus dorsi, triceps, and diaphragm) ( Figure 2B ). Only ISIS 486178 had an effect in the heart, with a 31% decrease in mutant transcripts, and no significant decrease was observed in the brain with either ASO, as expected based on poor blood-brain barrier penetration of ASOs. 21 These data indicate that the cEt-containing DMPK ASO ISIS 486178 is more efficient than the MOE ASO ISIS 445569 for targeting mutant transcripts in muscle tissues after systemic injection.
ISIS 486178 Increases Body Weight in DMSXL Mice
We have previously shown that homozygous DMSXL female mice have a reduced body weight compared to age-matched wild-type mice. 15 To determine whether the decrease in CUG exp RNAs by ASOs attenuate this loss in body weight, DMSXL mice were treated with 25 mg/kg of ISIS 486178 twice a week for 4 weeks. A significant increase in body weight was observed after 4 weeks of treatment (p = 0.016). On the other hand, no significant effect was observed with the less potent ASO ISIS 445569 (Table 1) .
ISIS 486178 Increases Muscle Strength in DMSXL Mice
Ideally, a therapeutic reduction of CUG exp RNAs would lead to increased muscle strength in the DMSXL mice. We have previously shown that these mice exhibit a 30% reduction in forelimb strength compared to age-matched wild-type mice using the grip test. 15 During the 2-month treatment period, untreated homozygous DMSXL mice lost 5.9 g in force, whereas treatment with ASO ISIS 486178 significantly increased muscle strength by 2.6 g (p = 0.003). A partial improvement of 0.5 g was seen following ISIS 445569 treatment, but was not significant when compared to average force variation in the DXSXL mice ( Figure 2C ). As in a previous characterization of these mice, 15 the correlation between strength phenotype and specific force was not possible (data not shown).
ISIS 486178 ASO Treatment Improves Skeletal Muscle Maturation in DMSXL Mice
Studies on rat soleus muscle development revealed an early muscle fiber distribution, with mixed fibers type 1/2a (2c) transitioning to type 1 after a few months of life. 22 Four-month-old DMSXL mice have been reported to exhibit a higher proportion of fibers 1/2a in soleus muscle than have age-matched wild-type mice, 15 which might be linked to delayed muscle fiber differentiation, as found in CDM1 patients. 2 This prompted us to investigate the possibility of reversing the persistent fiber immaturity profile following treatment with ASOs. Immunostaining of soleus muscle fibers, which express both myosin heavy chain 1 and 2a in 7-month-old homozygous DMSXL revealed a 2.7% abundance of type 1/2a fibers, whereas only 0.85% of these fibers can be observed in age-matched wild-type mice. Treatment of DMSXL mice with ASO ISIS 486178 restored 95% of the normal profile of type 1/2a fibers in DMSXL mice ( Figure 2E ).
ISIS 486178 ASO Treatment Causes No Overt Toxicity in DMSXL Mice
Treatment of DMSXL mice with ISIS 486178 and ISIS 445569 for 9 weeks was not associated with any mortality. One untreated DMSXL mouse died a few hours prior to necropsy, and another died before the first injection. No DMSXL mice treated with ASO ISIS 486178 and ISIS 445569 died during the experiment. No liver anomalies were visually detected during necropsy, whereas alkaline phosphatase (ALP), alanine transaminase (ALT), and aspartate transaminase (AST) blood levels all remained within normal limits, without any significant variation ( Figure 2D ). Likewise, creatine kinase (CPK) and creatinine (CRE) levels, which are markers for tissue and kidney damage, respectively, were shown to stay within the normal thresholds for the course of the experiment.
A microarray on tibialis anterior muscle samples from ISIS-486178treated DMSXL mice provided a good opportunity to examine its effect on the expression inflammation, necrosis, apoptosis, and other cell death genes using GO analysis. Only five endogenous genes were found to be downregulated by treatment (i.e., by R2-fold change; Table S2 ), namely Ibsp, Atp2a2, Meg3, Nnat, and Tpm3 (Figure 2F ). The microarray also corroborated our RT-qPCR results for Dmpk gene expression, with a 73% reduction.
Evaluation of ISIS 486178 ASO Treatment in Wild-Type Mice
Because the ISIS 486178 sequence also targets the endogenous mouse Dmpk transcripts, we next analyzed its effect in wild-type mice following s.c. injection. After 9 weeks of administration, a strong decrease in endogenous Dmpk mRNA was detected ( Figure S5 ). Despite the strong downregulation of Dmpk expression, no significant changes in growth, mortality, or muscle strength were detectable after treatment (data not shown). These results indicate that the decrease in endogenous Dmpk mRNA by ISIS 486178 had no effect on the DM1 phenotype, in good agreement with our previous data 19 and with data showing that knockout of the Dmpk gene in transgenic mice induce only a late-onset progressive myopathy. 23 The latter observations suggest that the residual Dmpk mRNA levels might be sufficient to counteract these effects and sustain normal function.
DISCUSSION
Homozygous DMSXL mice display high mortality during the first month of life, as well as growth retardation, decrease in muscle strength, motor performance, and cognitive impairments, but no or only mild myotonia. 16 Histological features of the skeletal muscles revealed a decrease in the mean muscle fiber cross-sectional area, an increase in the number of oxidative fibers, and an increase in mixed fibers 1/2a, which may point to a potential delay in muscle maturation. The clinical and histological manifestations observed in DMSXL mice are characteristically closer to those observed in the congenital rather than the adult form of the disease. The absence of the classical histological features observed in human DM1 skeletal muscle, such as type 1 fiber atrophy and type 2 fiber hypertrophy, ringed fibers, sarcoplasmic mass, and mild splicing abnormalities are also consistent with this observation. 1 There is indeed a lack of data for the involvement of the spliceopathy in the pathogenesis of the congenital form of the disease. Very mild and variable mis-splicings have been characterized in DMSXL mice 15 but did not prove to represent a significant measure of pathological outcome in this model for ASO screening. Insertional effects in DMSXL mice can be ruled out because parental homozygous mice carrying 500-600 repeats (DM300) have very mild or no detectable phenotype. 15, 24, 25 Shortterm therapy with ASOs produced a sustained phenotypic disease reversal, including gain of body weight, increase in muscle strength, and restoration in skeletal muscle maturation. These results show that muscle weakness in DM1 can be improved using a targeted approach to eliminate toxic RNAs. This indicates that muscle weakness may be reversible in a DM1 patient.
In this report, we demonstrate that a cEt-modified ASO (ISIS 486178) targeting DMPK mRNA significantly reduced mutant transcripts in cells and generates a reproducible and robust reduction in skeletal muscle DMPK mRNAs in DM1 mice following s.c. administration. The MOE gapmer ASOs have been shown to reduce mutant DMPK transcripts in the skeletal muscles of DMSXL mice following s.c. administration, but at higher doses than those required for the cEtmodified ASOs. A 50% and 75% reduction in DMPK RNAs were observed in skeletal muscles at 50 and 75 mg/kg, respectively, twice a week for 4 weeks using MOE gapmer ASOs. 18 The potent activity of cEt-modified oligonucleotides in skeletal muscle has also been demonstrated for an androgen receptor (AR) targeting ASO in AR transgenic mice. 26 Activity in skeletal muscle has also been described for a peptide-PMO conjugate, Pip5e-PMO, with a single dose of 12-25 mg/kg and showed highly efficient exon skipping and dystrophin production in mdx mice, with >80% dystrophin-positive fibers measured in all skeletal muscle groups after systemic injection. 27 In contrast with what was observed with the cEt-modified ASO in DMSXL mice, no phenotypic reversion was observed following systemic injection of 12 mg/kg Pip6a-PMO (more efficient peptide ASO than Pip5e-PMO) likely due to uncompromised muscle cell membranes in DMSXL mice (J. Puymirat, unpublished data). The difference between the dose of ASOs used in mdx and DMSXL mice may be explained by more than one factor. The physical chemical behavior of the neutral PMO to the negatively charged cEt ASO will affect cell intake. Second, there is the matter of the cell-penetrating peptide attached to the PMO, which may improve cell penetration. Lastly, it has been shown that the muscle membrane is more permeable in mdx but not DMSXL mice, 28 which may facilitate ASO delivery following systemic administration.
The design used for the cEt-modified ASO is an interesting tool to modulate genes in skeletal muscle upon systemic administration. The decrease of only 30% of DMPK transcripts found in the heart after systemic administration suggests that the delivery of ISIS 486178 displays tissue specificity. It is of note, however, that DM1 transcripts could be reduced by as much as 60% in the heart using a dose of 100 mg/kg/week. 19 Our data agree with previously published tissue distribution of cEt-gapmer ASO using a pan-oligonucleotide antibody. 29 The inability of ISIS 486178 to effectively cross the bloodbrain barrier indicates that other delivery methods will have to be considered for the treatment of DM1-related cognitive impairments. To this end, intraventricular administration in mice could potentially resolve this issue 30 and needs further investigation. In humans, intrathecal administration of the SPINRAZA ASO, which is designed to target motor neurons in patients with infantile spinal muscular atrophy (SMA), is being commercialized, 45 showing the potential of this approach in DM1.
The cEt chemistry has been shown to be 3-to 5-fold more potent than that of the MOE-modified ASOs and is comparable to that of LNAs; however, the cEt-modified nucleoside appears to be better tolerated than LNA. 32 Neither overt nor new toxicity was found to be associated with their use, in agreement with a previous report showing that the toxicity profile of cEt ASOs is very similar to that of MOE ASOs in mice and monkeys. 29 The 3-10-3 gapmer design also contributes to the low hepatoxicity by the limited amount of high-affinity modified nucleosides, which reduces highaffinity-induced imperfect hybridizations and, therefore, RNase H1-dependent non-specific toxicity. 33 In parallel to this study, a full toxicity evaluation of ASO ISIS 486178 was conducted in a cynomolgus monkey by Ionis Pharmaceuticals and provided sufficient basis to launch a phase I/II clinical evaluation of a similar class of DMPK ASO, ISIS-DMPK Rx . We have previously published the pharmacokinetics and pharmacodynamics for ASO ISIS 486178 in both normal mice and monkeys. The activity of the ASO was similar in wild-type mice and DMSXL mice, 19 supporting that the pharmacokinetic in this mouse model is not significantly different than that in wild-type mice. Finally, we present a preclinical evaluation of a gene therapy for DM1 based on the elimination of toxic RNAs.
cEt gapmer ASO chemistry opens new avenues for the development of gene therapies based on gene silencing for several muscular dystrophies, such as DM1.
This study provides evidence that muscle strength can be improved following elimination of toxic RNAs in patients with DM1. Further work is needed to determine the long-term effects and toxicity of ASOs, although we recently showed that the reduction of Dmpk RNA levels in muscle was maintained for up to 16 and 26 weeks post-treatment in mice and monkeys, respectively, 19 suggesting that these ASOs may be effective in the long term. This is in good agreement with a previous study showing that treatment of a DM1 mouse model with MOE ASO results in an improvement of symptoms for up to 12 months after discontinuation of treatment. 18 The long-term beneficial effect of ASO treatment is also in agreement with other studies showing the long-term usefulness of chemically modified ASO therapy for the treatment of liver diseases 34 and hypercholesterolemia. 35, 36 
MATERIALS AND METHODS

Antisense Oligonucleotides
Synthesis 31 and identification 19 of active ASOs was performed by Ionis Pharmaceuticals, as previously described, and blinded for our evaluation. The design included a central gap region of ten DNA nucleotides with either a MOE or cEt modification at both ends, with phosphorothioate for intersubunit linkage. ISIS 445569 is a 5-10-5 MOE gapmer with sequence 5 0 -CGGAGCGGTTGT GAACTGGC-3 018 and ISIS 486178 is a 3-10-3 cEt gapmer with sequence 5 0 -ACAATAAATACCGAGG-3 0 .
Cell Culture and Transfection
Human fetal normal and congenital fetal DM1 (carrying 3,200 repeats) muscle satellite cells, which were previously described, 37 were grown in MB-1 medium (Thermo Scientific) supplemented with BSA 0.5 mg/m (Sigma-Aldrich), insulin 5 mg/mL (Sigma-Aldrich), and dexamethasone 0.4 mg/mL (Sigma-Aldrich 
Immunostaining -FISH
Cells grown on gelatin-coated coverslips were fixed with pre-chilled 50% acetone/50% methanol (Fisher Scientific) for 5 min at À20 C. After blocking with 3% BSA (Sigma), coverslips were incubated at 37 C for 1 hr with MB1a(4A8) (MDA Monoclonal Antibody Resource) 38 mouse monoclonal immunoglobulin G1 (IgG1) antibody against MBNL1 (one-fourth in 1X PBS/3% BSA). Secondary antibody Alexa Fluor-488 goat a-mouse IgG (H+L) (Molecular Probes) was used at 4 mg/mL, followed by a 1-hr incubation at 37 C. Sense ribonuclear inclusions were detected intracellularly with a 5 0 -Cy3-labeled (CAG) 5 PNA probe (PNA Bio). Immunostaining was followed by 4% formaldehyde (Sigma-Aldrich) fixation and incubated for 20 hr at 37 C in hybridization buffer ( Quadriceps sense ribonuclear inclusions were detected on 10-mmthick transverse serial sections with a 5 0 -Cy3-labeled (CAG) 5 RNA probe (Sigma). Thawed cross-sections were fixed in 4% buffered formaldehyde (Microm Microtech) during 20 min and permeabilized in 1X PBS (Sigma)/2% acetone (Fisher Scientific) for 5 min. Using Discovery Ventana Automaton (Roche), as previously described, 39 sections were incubated for 7 hr at 44 C with the probe in RiboHybe reagent (Roche), then counterstained with Hoechst 14533 (Sigma) and mounted with VECTASHIELD H-1000 (Vector) mounting me-dium. Slide observations were performed using an Axioplan 2 Imaging microscope (Zeiss). Four transverse levels of every quadriceps specimen were studied. Each cryosection was randomly subdivided into three areas to assess nuclear foci-containing cells up to an observation threshold for positivity of >100 nuclei in each cryosection. Image acquisitions were performed using an LSM 510 Meta confocal microscope (Zeiss) and were composed using ImageJ 1.41 software.
Study Approval
All animal experiments were approved by the Institutional Animal Care and Use Committees at the CRCHU de Québec and Ionis Pharmaceuticals. 
Subcutaneous Injection of ASOs
All ASOs were dissolved in PBS. Doses of 25 mg/kg (ISIS 486178) or 50 mg/kg (ISIS 445569) were injected s.c. twice a week in the interscapular region for 4 weeks and then once a week for an additional 5-week interval. The doses used were selected based on preliminary dose-response experiments in heterozygous DMSXL mice. Injection volumes ranged from 50 to 250 mL.
Blood Chemistry
Mice blood was collected by cardiac puncture, transferred to serum separator tubes (BD Bioscience), left for 30 min at room temperature for coagulation, and centrifuged at 2,000 Â g for 15 min. Serum was transferred to new tubes and kept at À20 until analysis. Plasma serum AST, ALT, CRE, CPK, and ALP were determined using Olympus reagents and an Olympus AU400e analyzer.
Real-Time qPCR Assay
Total RNA was purified from mouse tibialis anterior, soleus, triceps, quadriceps, latissimus dorsi, diaphragm, heart, and brain after flash freezing in liquid nitrogen. The isolation process started with a crude homogenization of 25 mg of tissue in proteinase K solution ( Table  S3 ) on a LightCycler 480 II (Roche) using SYBR Green I Master hot start reaction mix.
RT-PCR Analysis of Alternative Splicing
The design of primer sets and targets for SORBS1, CAMK2G, DMD, PDLIM3, and TTN mis-spliced events were previously described (primers in Table S3 ). 20 
Transcriptome Analysis by Microarray
RNA was isolated from human fetal normal cells treated with both ASOs using QIAzol (QIAGEN). DNA microarray analyses were carried out with Affymetrix Human Gene 1.0 ST arrays (Affymetrix) according to their standard protocol. RNA from DMSXL mice treated with ISIS 486178 was isolated from tibialis anterior muscle using the proteinase K method. Six mice per condition were separated into two pooled groups for analysis. DNA microarray analyses were carried out with Affymetrix Mouse Gene 2.0 ST arrays according to the Affymetrix standard protocol. The amount of total RNA was measured using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific). Optical density values at 260/280 were consistently above 1.9. Total RNA quality was assayed on an Agilent BioAnalyzer (Agilent Technologies). Briefly, 200 ng of total RNA per sample was labeled using the Affymetrix GeneChip WT cDNA Synthesis and Amplification Kit protocol and hybridized to the arrays as recommended by the manufacturer (Affymetrix). The cRNA hybridization cocktail was incubated overnight at 45 C while rotating in a hybridization oven. After 16-hr hybridization, the cocktail was removed and the arrays were washed and stained in an Affymetrix GeneChip fluidics station 450, according to the Affymetrix-recommended protocol. The arrays were scanned using the Affymetrix GCS 3000 7G and Gene-Chip Operating Software (Affymetrix) to produce the intensity files. The background subtraction and normalization of probe set intensities was performed using the method of robust multiarray analysis (RMA) described previously. 40 For Affymetrix Human Gene 1.0 ST arrays, differentially expressed genes were identified by comparison of gene expression intensity using a moderated t test, and a Bayes smoothing approach was developed for a low number of repli-cates. 41 To correct for the effect of multiple testing, the false discovery rate was estimated from p values derived from the moderated t test statistics. 42 The analysis was performed using the affylmGUI Graphical User Interface for the Limma microarray package 43 and GO analysis using the GO enrichment functionality in the Partek Genomics Suite software. For Affymetrix Mouse Gene 2.0 ST arrays, the CHP files were imported and analyzed with the Transcriptome Analysis Console Software (Affymetrix). Microarray analyses were performed by the CHU de Québec Research Center (Centre de Recherche du Centre Hospitalier Universitaire) Gene Expression Platform.
Muscle Fiber Morphometry
Frozen transverse 10-mm serial sections of muscles were air-fixed on slides for 15 min and incubated for 1 hr in blocking solution (10% goat serum [Sigma-Aldrich]; 2% BSA [Sigma-Aldrich]; and 1X PBS [Sigma-Aldrich]) at room temperature. Sections were then incubated consecutively for 1 hr each at 37 C with two mouse monoclonal antibodies with different isotypes directed against myosin heavy chain type 1 (BA-D5, IgG2b; DSHB) and type 2a (SC-71, IgG1; DSHB). Secondary antibodies were 2.5 mg/mL Cy3 rabbit anti-mouse IgG1 (Novus Biologicals) and 5 mg/mL Alexa Fluor-350 goat anti-mouse IgG2b (Molecular Probes). Slides were mounted with Fluoromount (Sigma) and fixed with generic clear nail polish, and images were acquired with an Eclipse TE300 (Nikon) microscope. Counts of muscle fibers positive for type 1 and 2a myosin heavy chain were performed using ImageJ 1.47 software.
Grip Test
Mice grip strength was assessed using a Chatillon grip strength digital dynamometer (Columbus Instruments) using a previously described protocol. 44 
Statistical Analysis
Statistical analyses were performed using a two-tailed unpaired Student's t test with unequal variance, and p < 0.05 was considered significant. Foci in DMSXL mice quadriceps were analyzed by the Kryskall Wallis test, with p < 0.05 being considered significant. 
SUPPLEMENTAL INFORMATION
CONFLICTS OF INTEREST
Partial research support was funded by Ionis Pharmaceuticals, Inc. S.K.P., A.R.M., and C.F.B. were employees of Ionis Pharmaceuticals, Inc. and inventors on patent # WO2015021457A3 regarding ISIS 486178/ISIS 445569 antisense technology for modulation of DMPK expression.
